{"id":33020,"date":"2025-05-08T15:46:51","date_gmt":"2025-05-08T07:46:51","guid":{"rendered":"https:\/\/flcube.com\/?p=33020"},"modified":"2025-05-08T15:46:52","modified_gmt":"2025-05-08T07:46:52","slug":"beigenes-q1-2025-revenues-soar-49-yoy-driven-by-brukinsa-global-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33020","title":{"rendered":"BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales"},"content":{"rendered":"\n

BeiGene, Ltd. (NASDAQ: ONC<\/a>, HKG: 6160<\/a>, SHA: 688235<\/a>), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., released its Q1 2025 financial results. Total revenues reached USD 1.1 billion, marking a 49% year-on-year (YOY) increase. Brukinsa (zanubrutinib) played a significant role with global sales of USD 792 million, up 62% YOY.<\/p>\n\n\n\n

Product Revenue Growth<\/strong>
The increase in product revenue was primarily driven by stronger sales of Brukinsa. The U.S. remained the largest market for BeiGene, generating product revenue of USD 563 million in Q1 2025, compared to USD 351 million in the same period last year. In-licensed products from Amgen and Tevimb also contributed to the growth in product revenue. U.S. sales of Brukinsa alone reached USD 563 million in Q1 2025, a 60% increase from the prior-year period, primarily due to increased demand. More than 60% of the quarter-over-quarter growth stemmed from expanded use in chronic lymphocytic leukemia (CLL), with Brukinsa continuing to lead in new patient starts in the U.S. across CLL and all other approved indications. Brukinsa sales in Europe totaled USD 116 million in Q1 2025, a 73% increase from the prior-year period, driven by increased market share across major European markets, including Germany, Italy, Spain, France, and the UK. Sales of Tevimbra reached USD 171 million in Q1 2025, an 18% increase from the prior-year period.<\/p>\n\n\n\n

Financial Guidance<\/strong>
BeiGene projects total revenue of USD 4.9\u20135.3 billion for the year, reflecting strong growth expectations for Brukinsa’s U.S. market dominance and continued global expansion.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change…<\/p>\n","protected":false},"author":1,"featured_media":33021,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[185,2092,27,847,3046,848],"class_list":["post-33020","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-beigene","tag-beone-medicines","tag-finanical-reports","tag-hkg-6160","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"\nBeiGene's Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., released its Q1 2025 financial results. Total revenues reached USD 1.1 billion, marking a 49% year-on-year (YOY) increase. Brukinsa (zanubrutinib) played a significant role with global sales of USD 792 million, up 62% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33020\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene's Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales\" \/>\n<meta property=\"og:description\" content=\"BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., released its Q1 2025 financial results. Total revenues reached USD 1.1 billion, marking a 49% year-on-year (YOY) increase. Brukinsa (zanubrutinib) played a significant role with global sales of USD 792 million, up 62% YOY.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33020\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T07:46:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T07:46:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales\",\"datePublished\":\"2025-05-08T07:46:51+00:00\",\"dateModified\":\"2025-05-08T07:46:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0806.webp\",\"keywords\":[\"BeiGene\",\"BeOne Medicines\",\"Finanical Reports\",\"HKG: 6160\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33020#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33020\",\"name\":\"BeiGene's Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0806.webp\",\"datePublished\":\"2025-05-08T07:46:51+00:00\",\"dateModified\":\"2025-05-08T07:46:52+00:00\",\"description\":\"BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., released its Q1 2025 financial results. Total revenues reached USD 1.1 billion, marking a 49% year-on-year (YOY) increase. Brukinsa (zanubrutinib) played a significant role with global sales of USD 792 million, up 62% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33020\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0806.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeiGene's Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33020#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene's Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales - Insight, China's Pharmaceutical Industry","description":"BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., released its Q1 2025 financial results. Total revenues reached USD 1.1 billion, marking a 49% year-on-year (YOY) increase. Brukinsa (zanubrutinib) played a significant role with global sales of USD 792 million, up 62% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33020","og_locale":"en_US","og_type":"article","og_title":"BeiGene's Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales","og_description":"BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., released its Q1 2025 financial results. Total revenues reached USD 1.1 billion, marking a 49% year-on-year (YOY) increase. Brukinsa (zanubrutinib) played a significant role with global sales of USD 792 million, up 62% YOY.","og_url":"https:\/\/flcube.com\/?p=33020","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-08T07:46:51+00:00","article_modified_time":"2025-05-08T07:46:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33020#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33020"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales","datePublished":"2025-05-08T07:46:51+00:00","dateModified":"2025-05-08T07:46:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33020"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33020#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0806.webp","keywords":["BeiGene","BeOne Medicines","Finanical Reports","HKG: 6160","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33020#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33020","url":"https:\/\/flcube.com\/?p=33020","name":"BeiGene's Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33020#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33020#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0806.webp","datePublished":"2025-05-08T07:46:51+00:00","dateModified":"2025-05-08T07:46:52+00:00","description":"BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change its name to BeOne Medicines Ltd., released its Q1 2025 financial results. Total revenues reached USD 1.1 billion, marking a 49% year-on-year (YOY) increase. Brukinsa (zanubrutinib) played a significant role with global sales of USD 792 million, up 62% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33020#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33020"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33020#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0806.webp","width":1080,"height":608,"caption":"BeiGene's Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33020#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33020"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33020\/revisions"}],"predecessor-version":[{"id":33022,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33020\/revisions\/33022"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33021"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}